Immunotherapy

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.

Survival for people with hepatocellular carcinoma has improved over the last decade, according to study results.

The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a systematic review and meta-analysis.

Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.

The FDA approved tumor treating fields for use as part of combination treatment for certain patients with metastatic non-small cell lung cancer.

Healio’s Women in Allergy explored potential risks women may face associated with cooking exposures.

Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Inpatient management of people with cancer varied considerably based on their housing status, according to results of a cross-sectional study.

Healio has compiled September’s most-read news in asthma and allergy.